Korean Stem Cell Ventures Pursuing Divergent R&D Strategies

Two South Korean stem cell therapy ventures, Corestem and CHA Biotech, are taking divergent strategies in R&D and commercialization, one pushing ahead with the rapid launch of its first product and the other taking time to optimize its pipeline. During a recent stem cell industry investor relations session in Seoul, the companies unveiled the thinking behind their pipeline progress and business strategies.

SEOUL – South Korean stem cell bioventure Corestem Inc. has opted to conduct the entire process of R&D and commercialization for its first product candidate Neuronata-R in house, but aims to reduce risks for its subsequent pipeline by seeking partners in the early stages, as the stem cell market grows and research infrastructure for such therapies develops.

“The first business model we selected was a ‘biopharma model’ amid a lack of infrastructure and appropriate partners. We conducted...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia